Search For "controller"
SEC recommends COVID-19 vaccine Corbevax for 12-18 year age group: Sources
Updated : 4 years, 1 month ago IST
New Delhi [India], February 15 (ANI): The Drugs Controller General of India (DCGI)'s Subject Expert Committee (SEC) has recommended Emergency Use Authorization to Hyderabad-based pharmaceutical company Biological E's COVID-19 vaccine, Corbevax, for the age group 12 to 18 years subject to
Read More
Xbox Share button to soon get more customizable
Updated : 4 years, 1 month ago IST
Washington [US], February 8 (ANI): American tech giant Microsoft will soon be allowing Xbox Series X / S owners to fully customize the Share button on their controllers.
Read More
DCGI grants emergency-use approval to single-dose Sputnik Light COVID-19 v
Updated : 4 years, 1 month ago IST
New Delhi [India], February 6 (ANI): The Drugs Controller General of India (DCGI) has granted emergency-use permission to the single-dose Sputnik Light COVID-19 vaccine, informed Union Health Minister Mansukh Mandaviya on Sunday.
Read More
COVID-19: Nasal vaccine could be a game-changer if it provides mucosal imm
Updated : 4 years, 1 month ago IST
New Delhi [India], January 30 (ANI): As Hyderabad-based drug maker Bharat Biotech has got regulatory approval to conduct Phase-3 clinical trials of its intranasal COVID-19 vaccine as a booster dose, senior epidemiologist in All India Institute of Medical Sciences (AIIMS) in Delhi, Dr Sanjay
Read More
Bharat Biotech gets DCGI's nod to conduct intranasal booster dose trials
Updated : 4 years, 1 month ago IST
New Delhi [India], January 28 (ANI): The Drugs Controller General of India (DCGI) on Friday granted permission to Bharat Biotech to conduct clinical trials of intranasal vaccine BBV154.
Read More
DCGI grants conditional market approval for Covaxin, Covishield
Updated : 4 years, 1 month ago IST
New Delhi [India], January 27 (ANI): The Drugs Controller General of India (DCGI) on Thursday granted conditional regular market approval for COVID-19 vaccines Covaxin and Covishield for restricted use in emergency situations in the adult population.
Read More
Regular market approval to Covishield, Covaxin expected soon after final p
Updated : 4 years, 1 month ago IST
New Delhi [India], January 26 (ANI): The regular market approval from Drugs Controller General of India (DCGI) to COVID-19 vaccine Covishield and Covaxin is expected soon, but only after price fixation which is still underway, official sources told ANI on Wednesday.
Read More
SEC recommends regular market approval to Covaxin, Covishield for adults
Updated : 4 years, 1 month ago IST
New Delhi [India], January 19 (ANI): The Drugs Controller General of India's (DCGI) subject expert committee (SEC) has recommended the regular market approval to Serum Institute of India and Bharat Biotech for their COVID-19 vaccines Covaxin and Covishield with conditions for the adult po
Read More
Delhi HC refuses to entertain plea of ATC Guild India against random breat
Updated : 4 years, 1 month ago IST
New Delhi [India], January 19 (ANI): The Delhi High Court on Wednesday refused to entertain Air Traffic Controller (ATC) Guild India petition against conducting of random breath analyser (BA) tests on 5 per cent of the ATCs prior to joining duty at the airports during the surge of the COVID-
Read More
SEC asks for more data to grant full market approval to Covaxin and Covish
Updated : 4 years, 2 months ago IST
New Delhi [India], January 14 (ANI): The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) will continue thorough review of data submitted by the Serum Institute of India (SII) and Bharat Biotech for granting full market approval to Covaxin and Covishield, sources
Read More
ED attaches assets worth over Rs 2 crore of former deputy drug controller
Updated : 4 years, 2 months ago IST
New Delhi [India], January 14 (ANI): The Enforcement Directorate (ED) has attached assets worth Rs 2.07 crore of a former Deputy Drug Controller Licensing Authority Solan, Himachal Pradesh, and others in a disproportionate asset case.
Read More
DCGI's SEC to review applications of Bharat Biotech, SII for full market a
Updated : 4 years, 2 months ago IST
New Delhi [India], January 14 (ANI): Drugs Controller General of India (DCGI)'s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, sources said.
Read More